EATG » R&D

R&D

Immunocore and the Bill & Melinda Gates Foundation collaborate to develop immunotherapies for infectious diseases

$40 million investment to accelerate development of Immunocore’s ImmTAV® and ImmTAB® therapeutics for infectious diseases, in particular tuberculosis and HIV (Oxford, UK and Conshohocken, US 18 September 2017) Immunocore Limited,…

Declining funding and shrinking donor base imperils continued success of HIV prevention research

European countries called to renew support New York and Paris, July 20, 2017 — A new report released today ahead of the 9th IAS Conference on HIV Science documents 2016 funding…

2017 TAG Pipeline Report

TAG’s annual Pipeline Report: Promising new HIV, TB & HCV drugs and diagnostics New York, NY, July 18, 2017 – Treatment Action Group (TAG) announces the launch of its annual…

3P Project enables radical change in R&D for TB treatment

A new project that stimulates the development of affordable and effective drug regimens to treat tuberculosis (TB) is catching notice in policy circles. The “3P Project” is based upon the…

Media coverage of the 70th World Health Assembly

Intellectual Property Watch news coverage of the 70th World Health Assembly: Intellectual Property Watch: WHO official: Medicines should not be priced at the value of a life “Member governments of…

Expanding access to medicines: what role for transparency?

Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and…

Antimicrobial resistance needs new R&D models, NGOs say

A group of non-governmental organisations organised a side event to the World Health Assembly to discuss the growing issue of antimicrobial resistance, the way to incentivise research and development for…

WHO studies on local pharma production provide key contrasts between China, India

Two new studies published by the World Health Organization provide insight on the production of pharmaceutical products in India and China. According to the studies, China has a substantial local…

WHO, stakeholders take ‘first step’ on fair pricing for medicines

The World Health Organization has concluded a major one-day forum on fair pricing of medicines, bringing a wide range of stakeholders together in Amsterdam and coming up with several possible…

G20: Can the world’s richest economies innovate for global health?

The term “neglected tropical diseases” is on the way out. Instead, global health experts are beginning to favor the less geographically-restricted “neglected poverty-related diseases,” which reflects not only the borderlessness…